Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer

Administering NAC before surgery to patients in the high-risk subgroup was cost-effective at “normal” levels of willingness to pay, but not for the overall sample or for patients in the non-high-risk subgroup.